{"filing":{"accession_number":"0001193125-26-292677","cik":"0001585608","ticker":"JAGX","company_name":"Jaguar Health, Inc.","form":"8-K","filing_date":"2026-07-01","report_date":null,"primary_document":"d145900d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526292677/d145900d8k.htm"},"events":[{"id":15561,"run_id":13882,"accession_number":"0001193125-26-292677","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The filing discloses a special dividend of Series O Convertible Preferred Stock paid on March 4, 2026, followed by the automatic conversion of all outstanding Series O Preferred Stock into Common Stock on June 25, 2026, at a conversion ratio of 3.209 shares of Common Stock per preferred share. This conversion resulted in 4,857,211 shares of Common Stock outstanding and an additional 839,000 shares issuable upon warrant exercise, representing substantial dilution to existing common shareholders. While the event involves both a dividend distribution and a conversion, the material impact centers on the dilutive issuance of common shares through the preferred stock conversion mechanism.","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":13391,"accession_number":"0001193125-26-292677","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a special dividend of Series O Convertible Preferred Stock paid on March 4, 2026, followed by the automatic conversion of all outstanding Series O Preferred Stock into Common Stock on June 25, 2026, at a conversion ratio of 3.209 shares of Common Stock per preferred share. This conversion resulted in 4,857,211 shares of Common Stock outstanding and an additional 839,000 shares issuable upon warrant exercise, representing substantial dilution to existing common shareholders. While the event involves both a dividend distribution and a conversion, the material impact centers on the dilutive issuance of common shares through the preferred stock conversion mechanism.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T00:09:17.604543+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13391,"accession_number":"0001193125-26-292677","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a special dividend of Series O Convertible Preferred Stock paid on March 4, 2026, followed by the automatic conversion of all outstanding Series O Preferred Stock into Common Stock on June 25, 2026, at a conversion ratio of 3.209 shares of Common Stock per preferred share. This conversion resulted in 4,857,211 shares of Common Stock outstanding and an additional 839,000 shares issuable upon warrant exercise, representing substantial dilution to existing common shareholders. While the event involves both a dividend distribution and a conversion, the material impact centers on the dilutive issuance of common shares through the preferred stock conversion mechanism.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T00:09:17.604543+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-07-01"}]}